Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions.
Arnie AstrupPublished in: European journal of clinical nutrition (2024)
Scientists were chasing an incretin hormone, and when GLP-1 was finally discovered, we found that it had a pronounced satiety effect, slowed down gastric emptying, and actually reduced postprandial insulin response. These mechanisms are the basis for the highly efficacious GLP-1 analogues that today offer safe and effective treatment in millions of people living with obesity. Moreover, the combined GLP-1 mechanisms of weight loss and delayed carbohydrate absorption may also be the key drivers of remission of type 2 diabetes and reduced cardiovascular events found by GLP-1 analogues.
Keyphrases
- weight loss
- cardiovascular events
- type diabetes
- metabolic syndrome
- insulin resistance
- bariatric surgery
- coronary artery disease
- cardiovascular disease
- molecular docking
- roux en y gastric bypass
- glycemic control
- high fat diet induced
- gastric bypass
- mesenchymal stem cells
- stem cells
- high throughput
- blood pressure
- adipose tissue
- disease activity
- rheumatoid arthritis
- combination therapy
- obese patients
- molecular dynamics simulations
- skeletal muscle